Qsymia, the simply convenient choice for weight management.

Real Results With Qsymia

See the Proven Weight-Loss Results in Real Adult Patients

Extensively studied and prescribed, FDA-approved Qsymia is the once-daily pill that helps you manage your weight-loss plan and set realistic expectations.1,2

See the average results of 3,754 patients 18 years and older who were participating in the studies at the 12, 28 and 56-week time points. These are important time points to help your healthcare provider evaluate your status and assess your treatment plan.1,2†

The results presented here are from the combined studies supporting FDA approval of Qsymia. The dosing schedule in those studies differ from the dosing schedule that your physician may recommend. As a result of this dosing differential, your results may vary depending on your weight, BMI, diet, activity level, dose of Qsymia, and other factors.

Qsymia was studied in 2 large trials that involved 3,754 patients 18 years and older whose BMI was 27 kg/m2 or greater. For the subjects in the 2 studies the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg (starter dose), phentermine 7.5 mg/topiramate 46 mg (recommended dose), or phentermine 15 mg/topiramate 92 mg (top dose). In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day.

The chart presents data for patients who completed treatment at each time point. Some patients left the study or stopped taking Qsymia prior to completing the full 56 weeks. The drop off rate for placebo was 47% (687/1477), recommended dose was 31% (150/488) and top dose was 38% (561/1479). The most common reasons (>2% of patients) were: adverse events, patients lost to follow up, patients who withdrew consent, or lack of efficacy.

Analysis of all patients (including those who dropped off) results in slightly smaller reductions in weight and waist circumference. Weight loss in all patients was 4.7 lbs, 14.1 lbs, and 17.2 lbs with placebo, recommended dose, and top dose, respectively, at 12 weeks; 5.4 lbs, 19.5 lbs, and 24.3 lbs with placebo, recommended dose, and top dose, respectively, at 28 weeks; and 3.8 lbs, 19.5 lbs, and 24.7 lbs with placebo, recommended dose, and top dose, respectively, at 56 weeks. The reduction in waist circumference was 1.1 inches, 2.2 inches, and 2.5 inches with placebo, recommended dose, and top dose, respectively, at 12 weeks; 1.3 inches, 3.2 inches, and 3.7 inches with placebo, recommended dose, and top dose, respectively, at 28 weeks; and 1.2 inches, 3.4 inches, and 4.0 inches with placebo, recommended dose, and top dose, respectively, at 56 weeks.1,2

How similar is your journey? In a survey of 1,656 real Qsymia patients...
How similar is your journey? In a survey of 3,372 real Qsymia patients...
Over 50%

The top 3 life events leading to weight gain were:

  • Changes in metabolism
  • Stress or mental health
  • Demands of work and family life
 
Top 3

Indicated the reason they wanted to lose weight was to:

Become healthier and improve health conditions related to my weight

QSYMIA PATIENT SURVEY: Online survey conducted in August 2023. Responses from 1,656 Qsymia patients 18 years and older. Respondents were not remunerated for participating in the survey.

Qsymia, the simply convenient choice for weight management.

ASK ABOUT A NON INJECTION[SM] WEIGHT-MANAGEMENT TREATMENT OPTION

Lose weight and keep it off with diet, exercise and once-daily Qsymia.1,2

Qsymia Offers Real Control

Qsymia can help you take control of the hunger and cravings you struggle with.1

LEARN HOW

Multiple Ways to Save on Qsymia

Now it’s easier to get Qsymia, manage your plan and achieve your weight-loss goals!

SEE THE REAL SAVINGS

Indication

Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management inadults with an initial body mass index (BMI)…

Important Safety Information

Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors…

READ MORE